Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company specializing in endocrine diseases and tumors, revealed encouraging...
The new registry will prospectively collect detailed patient-level data enabling assessment of the natural history of the disease and treatment patterns, a...
BRUKINSA is the first and only BTK inhibitor approved across five oncology indications and the first and only approved in follicular lymphoma Approv...
Debiopharm a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectiou...
Immediately after the effective time of the Acquisition, and before giving effect to the concurrent private placement the former stockholders of Bi...
Exonate Ltd., a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases, today announ...
Clinical Microbiomics A/S^1, the global microbiome science company, announces the acquisition of DNASense ApS, an innovative Danish microbiome C...
NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, announced that...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to d...
-Medidata, a Dassault Systèmes company and leading provider of clinical trial solutions to the life sciences industry, today announced it has renewe...
In a significant breakthrough for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), Boehringer Ingelheim's latest Phase II clinical...
Sanofi-Aventis Groupe announced promising results from its Phase 2 RILECSU study, showcasing rilzabrutinib's ability to significantly reduce itch severity ...
LimmaTech Biologics AG, announced encouraging interim results from its Phase I/II clinical trial evaluating Shigella4V (S4V), a promising tetravalent bioco...
Polpharma Biologics' investigational biosimilar shows PK/PD comparability to inflammatory bowel disease blockbuster Entyvio® ...
© 2025 Biopharma Boardroom. All Rights Reserved.
